BioCardia, Inc.: Form 10-K for the period ended Dec 31, 2020
Filed with the SEC on Mar 30, 2021 and accepted by EDGAR at Mar 30, 2021, 07:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2020-01-01 to 2020-12-31 | $145.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 12 months2020-01-01 to 2020-12-31 | $4.0k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2020-01-01 to 2020-12-31 | $9.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2020-01-01 to 2020-12-31 | $5.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$15.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2020-01-01 to 2020-12-31 | $3.0k | us-gaap:InterestExpense |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$15.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | −$1.48 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$12.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $32.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-12-31 | $21.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $22.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $23.4m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $4.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $4.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $19.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-21-007543. Last ingested by Listed: Nov 10, 2026, 21:12 ET. Listed shows no prices and gives no investment advice.